CINECA IRIS Institutional Research Information System

ORLANDI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.831
AS - Asia 3.279
EU - Europa 3.025
SA - Sud America 428
Continente sconosciuto - Info sul continente non disponibili 265
AF - Africa 168
OC - Oceania 9
AN - Antartide 1
Totale 16.006
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.645
SG - Singapore 1.079
IT - Italia 989
CN - Cina 876
HK - Hong Kong 487
DE - Germania 466
SE - Svezia 465
BR - Brasile 354
VN - Vietnam 313
GB - Regno Unito 195
BG - Bulgaria 188
FR - Francia 173
CA - Canada 140
FI - Finlandia 135
TR - Turchia 105
IN - India 96
RU - Federazione Russa 84
JP - Giappone 73
UA - Ucraina 71
CI - Costa d'Avorio 67
AT - Austria 59
BD - Bangladesh 41
KR - Corea 35
CH - Svizzera 31
NL - Olanda 30
PL - Polonia 30
BE - Belgio 28
NG - Nigeria 25
MX - Messico 22
ID - Indonesia 21
PK - Pakistan 21
AR - Argentina 19
IQ - Iraq 19
SA - Arabia Saudita 19
SN - Senegal 19
EC - Ecuador 15
ES - Italia 15
MA - Marocco 15
ZA - Sudafrica 15
UZ - Uzbekistan 14
VE - Venezuela 13
CO - Colombia 12
CZ - Repubblica Ceca 11
PH - Filippine 10
AU - Australia 9
JO - Giordania 9
DK - Danimarca 8
LT - Lituania 8
IR - Iran 7
IE - Irlanda 6
PS - Palestinian Territory 6
CL - Cile 5
EG - Egitto 5
GR - Grecia 5
MY - Malesia 5
NP - Nepal 5
TW - Taiwan 5
AL - Albania 4
CR - Costa Rica 4
ET - Etiopia 4
HU - Ungheria 4
JM - Giamaica 4
KH - Cambogia 4
LB - Libano 4
NO - Norvegia 4
PY - Paraguay 4
RS - Serbia 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
BB - Barbados 3
BJ - Benin 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
HN - Honduras 3
KE - Kenya 3
RO - Romania 3
TH - Thailandia 3
UY - Uruguay 3
AM - Armenia 2
BH - Bahrain 2
HR - Croazia 2
IL - Israele 2
MD - Moldavia 2
OM - Oman 2
PE - Perù 2
PT - Portogallo 2
A1 - Anonimo 1
AG - Antigua e Barbuda 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CY - Cipro 1
EE - Estonia 1
EU - Europa 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
GS - Georgia del Sud e Isole Sandwich Australi 1
Totale 15.732
Salva come PNG Salva come JPEG
Città #
Ashburn 927
Woodbridge 834
Fairfield 612
Singapore 605
Ann Arbor 603
San Jose 547
Dallas 517
Hong Kong 478
Houston 467
Chandler 458
Santa Clara 437
Seattle 308
Wilmington 256
Cambridge 232
Serra 218
Shanghai 193
Sofia 187
Beijing 183
New York 183
Milan 158
Los Angeles 155
Boardman 114
Munich 102
Ottawa 85
Council Bluffs 84
Princeton 84
Ho Chi Minh City 77
Lawrence 75
Lauterbourg 74
Medford 69
Abidjan 67
Tokyo 65
Jacksonville 64
Pisa 63
Dong Ket 60
Des Moines 59
Hanoi 59
London 55
Dearborn 53
Florence 52
Izmir 50
Vienna 49
Frankfurt am Main 45
Turku 45
Hefei 44
Rome 43
Buffalo 40
Istanbul 38
Nanjing 38
Helsinki 32
Seoul 32
Ogden 31
Redondo Beach 30
São Paulo 30
Boulder 29
Columbus 29
Brussels 28
San Diego 28
Düsseldorf 27
The Dalles 27
Denver 26
Falls Church 24
Fuzhou 24
Lagos 24
Bremen 23
Nanchang 23
Orem 22
Warsaw 22
Phoenix 21
Bern 20
Dakar 19
Marseille 19
Lucca 18
Montreal 18
Pune 18
Redwood City 18
Da Nang 16
Boston 15
Stockholm 15
Atlanta 14
Nürnberg 14
Toronto 14
Quanzhou 13
Shenyang 13
Lancaster 12
Rho 12
San Francisco 12
Hebei 11
Kunming 11
Norwalk 11
Nuremberg 11
Rio de Janeiro 11
Tashkent 11
Vicopisano 11
Baltimore 10
Brooklyn 10
Jüchen 10
Seacroft 10
Belo Horizonte 9
Chennai 9
Totale 11.258
Salva come PNG Salva come JPEG
Nome #
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients 547
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions 418
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 303
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy 284
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib 274
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. 267
Gender, MGMT methylation, and levetiracetam plasma levels correlate with survival benefit in glioblastoma patients treated with adjuvant temozolomide: results from a non-interventional retrospective clinical study 259
VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 256
Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy 256
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 255
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 253
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 248
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study 245
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 244
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 244
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients 243
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 238
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2 215
Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo 210
The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. 208
Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies. 206
Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. 201
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 197
Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy 196
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 193
Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib 190
Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation 186
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 180
Low-dose metronomic cyclophosphamide plus celecoxib and dexamethasone in advanced hormone refractory prostate cancer (HRPC): a phase II clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination 177
Old and New Systemic Immune-Inflammation Indexes Are Associated with Overall Survival of Glioblastoma Patients Treated with Radio-Chemotherapy 174
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells 174
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 172
Genetic interaction analysis of VEGF-A rs3025039 and VEGFR-2 rs2071559 identifies a genetic profile at higher risk to develop nodular goiter 171
In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists 170
Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib ( C ) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): preliminary clinical and pharmacodynamic results 169
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 169
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. 168
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 164
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 164
Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma 158
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells 158
Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer 156
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells 155
Irinotecan Metronomic Chemotherapy (MC) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation 151
Overexpression and functional relevance of somatostatin receptor-1, -2, and -5 in endometrium and endometriotic lesions 151
Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). 151
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer 150
Agenti melanocortinici per l’impiego nel trattamento terapeutico del melanoma, dei tumori del tratto gastroenterico e del carcinoma tiroideo 150
Prevention of capecitabine toxicity using a 5-FU test dose 148
Polymorphisms interaction to predict bevacizumab (BV) efficacy in metastatic breast cancer (MBC) patients: an exploratory retrospective analysis. 146
Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1 146
In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma 145
Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors 144
IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 143
A new biometric tool for three-dimensional subcutaneous tumor scanning in mice. 142
Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer 142
Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation. Final report 141
Pilot study of correlation between single nucleotide polymorphisms (SNPS) of pro-and anti-angiogenic genes and response to bevacizumab (BV) plus chemotherapy (CT) in patients with metastatic breast cancer (MBC) 140
MELANOCORTIN AGENTS FOR USE IN THE THERAPEUTIC TREATMENT OF MELANOMA, TUMORS OF THE GASTROINTESTINAL TRACT, AND THYROID CARCINOMA 135
Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma 134
Synergistic activity of linifanib and irinotecan increases the survival of mice bearing orthotopically implanted human anaplastic thyroid cancer 134
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients 132
Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial. 131
Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical and pharmacodynamic evaluation 130
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients 130
Antiangiogenic drugs in NASH: Evidence of a possible new therapeutic approach 130
null 127
Polymorphisms interaction to predict bevacizumab (BV) efficacy in metastatic breast cancer (MBC) patients (pts): An exploratory retrospective analysis. 125
Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells 125
Gender, MGMT methylation, and levetiracetam plasma levels correlate with survival benefit in glioblastoma patients treated with adjuvant temozolomide: results from a non-interventional retrospective clinical study 125
Vascular endothelial growth factor-A (VEGF-A) single nucleotide polymorphisms and endometriosis: still a controversial issue 123
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 121
Idarubicin and idarubicinol effects on breast cancer multicellular spheroids 121
Phase II clinical trial with pharmacodynamic evaluation of docetaxel/prednisone plus metronomic cyclophosphamide and celecoxib as first line treatment in metastatic hormone refractory prostate cancer (MHRPC) 120
Predictive Power of Tissue and Circulating Biomarkers for the Severity of Biopsy-Validated Chronic Liver Diseases 119
Melanocortin-4 Receptor Antagonism Inhibits Colorectal and Anaplastic Thyroid Cancer In Vitro and In Vivo 119
Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer 119
All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma 116
null 114
Correction to: Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy 112
Preclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer 112
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients 111
Discovery of a Potent Dual Inhibitor of Aromatase and Aldosterone Synthase 110
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. 109
Metronomic Chemotherapy in Elderly Patients 107
Polimorfismi genetici del VEGF e DMLE 105
null 101
Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward 90
null 89
null 76
Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-fluorouracil Antitumor Activity In Vitro and In Vivo 73
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer 73
Mathematical analysis of metronomic chemotherapy response in metastatic gastrointestinal cancer: identifying critical parameters from clinical data 70
Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cells 67
Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathway 53
Digital Microneedles for Multiplexed Transdermal Sensing via Fluorescent QR Codes 48
GABAergic signaling in colorectal cancer: Mechanistic insights, tumor microenvironment crosstalk, and therapeutic opportunities 46
null 46
Synergistic activity of tafasitamab and metronomic chemotherapy on diffuse large B-cell lymphoma through inhibition of the AKT/mTOR signaling pathway 45
Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival 19
Totale 15.997
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.866
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.866
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022917 14 71 21 32 154 154 26 34 53 40 54 264
2022/20231.467 175 223 126 128 158 187 9 104 259 6 80 12
2023/2024850 82 97 93 56 101 167 26 48 18 22 53 87
2024/20252.993 17 114 43 192 302 325 228 126 302 390 331 623
2025/20264.271 285 410 503 323 407 264 630 220 241 368 476 144
2026/2027237 237 0 0 0 0 0 0 0 0 0 0 0
Totale 16.006